Protagonist Therapeutics, Inc
Protagonist Therapeutics is an integrated drug discovery and development company focused on inflammation and immunology, hematology, and metabolic diseases. Its programs use a proprietary peptide technology platform. Products and candidates include Icotyde, an oral IL-23 receptor antagonist licensed to Janssen Biotech; rusfertide, an injectable hepcidin mimetic partnered with Takeda for polycythemia vera; and the wholly owned PN-881, an oral IL-17 antagonist. Its obesity program includes PN-477 and PN-458, peptide receptor agonists being developed in oral and subcutaneous formulations, while PN-8047 is an oral hepcidin mimetic candidate. The company also has preclinical discovery programs, including an oral IL-4R alpha antagonist and amylin receptor-based candidates. Protagonist makes money through collaboration agreements, including upfront and milestone payments and royalties on licensed products. Its Takeda agreement also provides for sharing U.S. profits and losses on rusfertide unless Protagonist exercises its opt-out right. Protagonist is headquartered in Newark, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PTGX in the last 30 days.
See all $PTGX insider activity →UBS reiterated a Buy rating and $184 price target for Protagonist Therapeutics (PTGX), citing progress in Mimrylo's launch. The stock has risen 83.5% over the past year. UBS attended a medical conference and noted favorable adoption prospects among specialists. PTGX recently received FDA approval for Mimrylo and Icotyde, leading to multiple analyst upgrades.
iShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.
Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PTGX (Protagonist Therapeutics, Inc). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent PTGX coverage spans financial news, insider activity and regulation.
Analyst upgrades and FDA approval suggest upside potential.
The reported reduction may weigh on near-term sentiment, but it is not a fundamental update for PTGX.
Regulatory approval and milestone cash flow support modest bullish bias.
Analyst coverage may improve market perception and support price gains.
Street initiation frames PTGX as undervalued versus its pipeline and Mimrylo royalty revisions, supporting bullish positioning.
AlphAI scores every news story that mentions PTGX with an AI model for sentiment and relevance, and aggregates insider trades from Protagonist Therapeutics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS reiterated a Buy rating and $184 price target for Protagonist Therapeutics (PTGX), citing progress in Mimrylo's launch. The stock has risen 83.5% over the past year. UBS attended a medical conference and noted favorable adoption prospects among specialists. PTGX recently received FDA approval for Mimrylo and Icotyde, leading to multiple analyst upgrades.
2 min readiShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.
5 min readDisc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
2 min readLeerink Partners selected Nektar Therapeutics (NKTR), Protagonist Therapeutics (PTGX), and Shattuck Labs (STTK) as top picks in emerging immunology. The firm highlighted NKTR's phase 3 asset rezpegaldesleukin for atopic dermatitis. PTGX and STTK were also noted for their potential.
1 min readUBS initiated coverage on Protagonist Therapeutics (PTGX) with a buy rating and $184 price target, citing drug potential. The stock is up 64.56% YTD. UBS highlights PN-881 as a key driver and expects upward revisions to Mimrylo royalties. Other analysts have also raised price targets following FDA approvals of Mimrylo and Icotyde.
3 min readAli Asif (Chief Financial Officer) sold 58,629 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $141.78 ($141.77–$141.78, $8.31M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.
1 min readProtagonist Therapeutics (PTGX) CEO Dinesh V. Patel exercised 125,000 stock options at $21.58 per share and sold the shares over three days in September 2026 under a 10b5-1 plan. The weighted average sale prices were $145.87, $146.18, and $144.10 per share, respectively, totaling approximately $18.24M in gross proceeds.
2 min readPATEL DINESH V PH D (President and CEO) sold 125,000 shares of Protagonist Therapeutics, Inc (PTGX) at an average of $145.92 ($144.10–$146.18, $18.24M total) across 3 trades over 2026-09-08 to 2026-09-10 under a Rule 10b5-1 trading plan.
1 min readProtagonist Therapeutics (PTGX) announced a $300M share repurchase program, funded by cash reserves and collaboration payments. The program may be executed through open market purchases or other transactions, with timing and amounts dependent on market conditions and other factors. As of June 30, 2026, the company had $849.5M in cash, cash equivalents, and marketable securities, excluding recent milestone payments.
2 min readProtagonist Therapeutics (PTGX) reported a $162.8M profit in Q2 2026, reversing a $34.8M loss from the prior year. The turnaround was driven by milestone payments for two drugs, ICOTYDE and rusfertide, with cash reserves reaching $849.5M. ICOTYDE, approved for psoriasis, triggered a $50M payment and potential $580M more from J&J. Rusfertide, awaiting FDA decision, has already brought in $200M from Takeda, with more milestones pending.
3 min read
